Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Imuldosa. Always confirm against the full prescribing information.
100 interactions
Abacavir
Abacavir may increase the hepatotoxic activities of Ustekinumab.
Level 2 evidence
Abatacept
Abatacept may increase the hepatotoxic activities of Ustekinumab.
Level 2 evidence
Abemaciclib
Ustekinumab may increase the hepatotoxic activities of Abemaciclib.
Level 2 evidence
Abiraterone
Abiraterone may increase the hepatotoxic activities of Ustekinumab.
Level 2 evidence
Acamprosate
Acamprosate may increase the hepatotoxic activities of Ustekinumab.
Level 2 evidence
Acarbose
Acarbose may increase the hepatotoxic activities of Ustekinumab.
Level 2 evidence
Acebutolol
Acebutolol may increase the hepatotoxic activities of Ustekinumab.
Level 2 evidence
Aceclofenac
Ustekinumab may increase the hepatotoxic activities of Aceclofenac.
Level 2 evidence
Acetaminophen
Acetaminophen may increase the hepatotoxic activities of Ustekinumab.
Level 2 evidence
Acetazolamide
Acetazolamide may increase the hepatotoxic activities of Ustekinumab.
Level 2 evidence
Acetylsalicylic acid
Acetylsalicylic acid may increase the hepatotoxic activities of Ustekinumab.
Level 2 evidence
Acitretin
Acitretin may increase the hepatotoxic activities of Ustekinumab.
Level 2 evidence
Enter your NPI to unlock 1 major interaction for Imuldosa
Imuldosa (Ustekinumab-Srlf) has 642 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Imuldosa (Ustekinumab-Srlf) has 2 major, 1 moderate, and 639 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Imuldosa. Always confirm against the full prescribing information.